Business Standard

Dr Reddy's Q4 PAT falls 76% YoY on impairment costs; misses estimates

The company's board also recommended a final dividend of Rs 30 per equity share of face value of Rs. 5 each for the financial year 2021-22.

pharma
Premium

Harshita Singh New Delhi
Dr Reddy's Laboratories, on Thursday, posted a 76 per cent year-on-year (YoY) decline in consolidated net profit at Rs 88 crores for the fourth quarter of financial year (Q4FY22), missing analyst estimates. This was due to impairment charges of Rs 751.5 crores during the quarter.

The company's revenue came at Rs 5,437 crores, up 15 per cent from last year, on strong growth across all markets. 

The company's board also recommended a final dividend of Rs 30 per equity share of face value of Rs. 5 each for the financial year 2021-22. 

Co-Chairman and MD G.V.Prasad said that

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in